Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes.

Rivière I, Sadelain M, Brentjens RJ.

Curr Hematol Rep. 2004 Jul;3(4):290-7. Review.

PMID:
15217559
2.

Targeting tumours with genetically enhanced T lymphocytes.

Sadelain M, Rivière I, Brentjens R.

Nat Rev Cancer. 2003 Jan;3(1):35-45. Review.

PMID:
12509765
3.

Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.

Berry LJ, Moeller M, Darcy PK.

Tissue Antigens. 2009 Oct;74(4):277-89. doi: 10.1111/j.1399-0039.2009.01336.x. Review.

PMID:
19775368
4.

Antigen choice in adoptive T-cell therapy of cancer.

Offringa R.

Curr Opin Immunol. 2009 Apr;21(2):190-9. doi: 10.1016/j.coi.2009.02.006. Review.

PMID:
19297140
5.
6.

CAR mechanics: driving T cells into the MUC of cancer.

Maher J, Wilkie S.

Cancer Res. 2009 Jun 1;69(11):4559-62. doi: 10.1158/0008-5472.CAN-09-0564. Review.

7.

Improving the efficacy and safety of engineered T cell therapy for cancer.

Shi H, Liu L, Wang Z.

Cancer Lett. 2013 Jan 28;328(2):191-7. doi: 10.1016/j.canlet.2012.09.015. Review.

PMID:
23022475
8.

TCR-engineered, customized, antitumor T cells for cancer immunotherapy: advantages and limitations.

Chhabra A.

ScientificWorldJournal. 2011 Jan 5;11:121-9. doi: 10.1100/tsw.2011.10. Review.

9.

The T-body approach: redirecting T cells with antibody specificity.

Eshhar Z.

Handb Exp Pharmacol. 2008;(181):329-42. Review.

PMID:
18071952
10.

Adoptive T-cell therapy of cancer.

Yee C.

Hematol Oncol Clin North Am. 2006 Jun;20(3):711-33. Review.

PMID:
16762731
11.

Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy.

Thistlethwaite F, Mansoor W, Gilham DE, Hawkins RE.

Curr Opin Mol Ther. 2005 Feb;7(1):48-55. Review.

PMID:
15732529
12.

Cellular immunotherapy of cancer.

Yang JC.

Curr Opin Gen Surg. 1994:238-44. Review.

PMID:
7583979
13.

The promise and potential pitfalls of chimeric antigen receptors.

Sadelain M, Brentjens R, Rivière I.

Curr Opin Immunol. 2009 Apr;21(2):215-23. doi: 10.1016/j.coi.2009.02.009. Review.

PMID:
19327974
14.

Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function.

Landmeier S, Altvater B, Pscherer S, Eing BR, Kuehn J, Rooney CM, Juergens H, Rossig C.

Cancer Res. 2007 Sep 1;67(17):8335-43.

15.

Genetically modulating T-cell function to target cancer.

Merhavi-Shoham E, Haga-Friedman A, Cohen CJ.

Semin Cancer Biol. 2012 Feb;22(1):14-22. doi: 10.1016/j.semcancer.2011.12.006. Review.

PMID:
22210183
16.

T cell immunotherapy.

McKee MD, Fichera A, Nishimura MI.

Front Biosci. 2007 Jan 1;12:919-32. Review.

PMID:
17127349
17.

Supernatural T cells: genetic modification of T cells for cancer therapy.

Kershaw MH, Teng MW, Smyth MJ, Darcy PK.

Nat Rev Immunol. 2005 Dec;5(12):928-40. Review.

PMID:
16322746
18.

Preclinical development of T cell receptor gene therapy.

Bendle GM, Haanen JB, Schumacher TN.

Curr Opin Immunol. 2009 Apr;21(2):209-14. doi: 10.1016/j.coi.2009.02.007. Review.

PMID:
19321326
19.

Designing TCR for cancer immunotherapy.

Voss RH, Kuball J, Theobald M.

Methods Mol Med. 2005;109:229-56.

PMID:
15585925
20.

Genetic modification of T lymphocytes for adoptive immunotherapy.

Rossig C, Brenner MK.

Mol Ther. 2004 Jul;10(1):5-18. Review.

PMID:
15233937
Items per page

Supplemental Content

Support Center